All News


 

2017

May

Media Release / May 02, 2017

Sandoz Canada launches PrSandoz® Olmesartan for the treatment of high blood pressure

Read More

April

Media Release / Apr 28, 2017

Community Partnership Day

Read More
Media Release / Apr 21, 2017

Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*

Read More
Media Release / Apr 18, 2017

Sandoz Canada launches Mosaspray™ in Québec: a non-prescription mometasone nasal spray for the treatment of the symptoms of allergic rhinitis

Read More

March

Media Release / Mar 06, 2017

New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

Read More

January

Media Release / Jan 31, 2017

Sandoz Canada launches Sandoz® Amphetamine XR for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Read More
2016

July

Media Release / Jul 07, 2016

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Read More

June

Media Release / Jun 28, 2016

Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada

Read More
Media Release / Jun 21, 2016

Sandoz Canada Launches First Non-Prescription Naloxone Approved by Health Canada for Treating Opioid Overdoses

Read More
Media Release / Jun 13, 2016

Sandoz Canada concludes a new collective agreement with unionized employees at its Boucherville plant

Read More